MCID: PPL007
MIFTS: 43

Papillary Serous Adenocarcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Papillary Serous Adenocarcinoma

Aliases & Descriptions for Papillary Serous Adenocarcinoma:

Name: Papillary Serous Adenocarcinoma 12 14
Serous Surface Papillary Carcinoma 12 69
Papillary Serous Cystadenocarcinoma 69
Micropapillary Serous Carcinoma 12
Papillary Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2632
SNOMED-CT 64 15674004 90282004

Summaries for Papillary Serous Adenocarcinoma

Disease Ontology : 12 A papillary adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures with psammoma bodies.

MalaCards based summary : Papillary Serous Adenocarcinoma, also known as serous surface papillary carcinoma, is related to primary peritoneal carcinoma and ovary papillary carcinoma. An important gene associated with Papillary Serous Adenocarcinoma is PGR (Progesterone Receptor), and among its related pathways/superpathways are Glioma and DNA Damage. The drugs Carboplatin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, cervix and breast, and related phenotypes are Synthetic lethal with cisplatin and behavior/neurological

Related Diseases for Papillary Serous Adenocarcinoma

Diseases related to Papillary Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
id Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 11.9
2 ovary papillary carcinoma 11.2
3 uterine corpus serous adenocarcinoma 11.0
4 adenocarcinoma 10.5
5 chromophil adenoma of the kidney 10.2 KRT20 NKX2-1
6 spasmodic dysphonia 10.2 KRT20 NKX2-1
7 agenesis and aplasia of uterine body 10.2 KRT20 NKX2-1
8 bone marrow cancer 10.2 NKX2-1 PGR
9 histiocytic and dendritic cell cancer 10.2 BRCA1 PGR
10 mesenchymoma 10.2 KRT20 PGR
11 chondroblastoma 10.2 KRT20 NKX2-1
12 aortitis 10.2 PGR TP53
13 hunter macpherson syndrome 10.2 KRT20 NKX2-1
14 pericardium leiomyoma 10.2 PGR TP53
15 breast ductal carcinoma 10.2 PGR TP53
16 acinar cell carcinoma 10.1 PGR TP53
17 aorto-ventricular tunnel 10.1 BRCA1 BRCA2
18 classic congenital mesoblastic nephroma 10.1 PGR TP53
19 burn scar 10.1 BRCA1 BRCA2
20 gastrointestinal system cancer 10.1 NKX2-1 PGR
21 kunjin encephalitis 10.1 BRCA1 BRCA2
22 lethal congenital contracture syndrome 7 10.1 BRCA1 BRCA2
23 neurofibrosarcoma 10.1 BRCA2 KRT20
24 vaginal adenosarcoma 10.1 PGR TP53
25 anus adenocarcinoma 10.1 KRT20 PGR
26 bronchogenic cyst 10.1 BRCA1 BRCA2
27 tmem70 defect 10.1 NKX2-1 TP53
28 central nervous system mature teratoma 10.1 PGR TP53
29 bronchiectasis oligospermia 10.1 BRCA1 BRCA2
30 seminoma 10.1 PGR TP53
31 pancreatic agenesis 10.1 KRT20 NKX2-1
32 kidney disease 10.1 NKX2-1 TP53
33 chronic endophthalmitis 10.1 BRCA1 BRCA2
34 bone deterioration disease 10.1 NKX2-1 TP53
35 neuropathy, distal hereditary motor, type viib 10.1 BRCA1 BRCA2
36 papillary carcinoma 10.1
37 exudative glomerulonephritis 10.1 NKX2-1 TP53
38 small intestine leiomyoma 10.1 KRT20 TP53
39 frontal sinusitis 10.1 BRCA1 BRCA2
40 clear cell hidradenoma 10.1 KRT20 TP53
41 spiradenoma 10.1 KRT20 TP53
42 male reproductive organ benign neoplasm 10.1 PGR TP53
43 bacteremia 10.1 BRCA1 BRCA2
44 lung clear cell carcinoma 10.1 KRT20 PGR
45 central nervous system primitive neuroectodermal neoplasm 10.1 PGR TP53
46 syndromic x-linked intellectual disability 14 10.1 BRCA1 BRCA2
47 reactive arthritis 10.1 PGR TP53
48 spastic ataxia 5 10.1 KRT20 TP53
49 giant cell tumor 10.1 KRT20 TP53
50 arthus reaction 10.1 PGR TP53

Graphical network of the top 20 diseases related to Papillary Serous Adenocarcinoma:



Diseases related to Papillary Serous Adenocarcinoma

Symptoms & Phenotypes for Papillary Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Papillary Serous Adenocarcinoma:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 BRCA1 BRCA2 NKX2-1 PGR PTGER4 STK36
2 cellular MP:0005384 10.05 BRCA1 BRCA2 NKX2-1 PGR PTGER4 STK36
3 homeostasis/metabolism MP:0005376 10 TP53 BRCA1 BRCA2 NKX2-1 PGR PTGER4
4 endocrine/exocrine gland MP:0005379 9.97 BRCA1 BRCA2 NKX2-1 PGR STK36 TP53
5 hematopoietic system MP:0005397 9.95 BRCA1 BRCA2 PGR PTGER4 STK36 TP53
6 immune system MP:0005387 9.91 BRCA1 BRCA2 PGR PTGER4 STK36 TP53
7 mortality/aging MP:0010768 9.91 BRCA1 BRCA2 NKX2-1 PGR PTGER4 STK36
8 integument MP:0010771 9.8 BRCA1 BRCA2 PGR PTGER4 TP53
9 neoplasm MP:0002006 9.8 BRCA1 BRCA2 NKX2-1 PGR PTGER4 TP53
10 normal MP:0002873 9.73 BRCA1 BRCA2 NKX2-1 PGR PTGER4 TP53
11 reproductive system MP:0005389 9.63 BRCA1 BRCA2 NKX2-1 PGR STK36 TP53
12 respiratory system MP:0005388 9.35 STK36 TP53 BRCA1 NKX2-1 PTGER4
13 skeleton MP:0005390 9.17 BRCA1 BRCA2 NKX2-1 PGR PTGER4 STK36

Drugs & Therapeutics for Papillary Serous Adenocarcinoma

Drugs for Papillary Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
4
Epirubicin Approved Phase 3 56420-45-2 41867
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
7
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
8
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
9
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
10
Doxil Approved June 1999 Phase 3,Phase 2 31703
11 Antimitotic Agents Phase 2, Phase 3, Phase 1
12 Hormones Phase 2, Phase 3
13 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
15 Topoisomerase Inhibitors Phase 3,Phase 2
16 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
17 Liver Extracts Phase 3,Phase 2
18 Antineoplastic Agents, Hormonal Phase 2, Phase 3
19 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1
20 Bone Density Conservation Agents Phase 2, Phase 3
21 Estrogen Receptor Modulators Phase 2, Phase 3
22 Estrogens Phase 2, Phase 3
23 Hormone Antagonists Phase 2, Phase 3
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
25 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
26 Selective Estrogen Receptor Modulators Phase 2, Phase 3
27 Anticoagulants Phase 2, Phase 3
28 Aromatase Inhibitors Phase 2, Phase 3
29 Calcium, Dietary Phase 2, Phase 3
30 Chelating Agents Phase 2, Phase 3
31 Estrogen Antagonists Phase 2, Phase 3
32 Steroid Synthesis Inhibitors Phase 2, Phase 3
33 topoisomerase I inhibitors Phase 2, Phase 3
34 Citrate Nutraceutical Phase 2, Phase 3
35
Citric Acid Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
36
Cimetidine Approved Phase 2 51481-61-9 2756
37
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
38
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
39
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
40
Promethazine Approved Phase 2 60-87-7 4927
41
Ifosfamide Approved Phase 2 3778-73-2 3690
42
Mechlorethamine Approved Phase 2 51-75-2 4033
43
Mesna Approved Phase 2 3375-50-6 598
44
Bevacizumab Approved, Investigational Phase 2 216974-75-3
45
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
46
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
47
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
48
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
49
Toremifene Approved, Investigational Phase 2 89778-26-7 3005573
50
nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show all 44)
id Name Status NCT ID Phase
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3
3 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
4 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3
5 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
6 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
7 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
8 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
9 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2
10 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2
11 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2
12 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2
13 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2
14 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2
15 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2
16 Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Completed NCT00052312 Phase 2
17 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2
18 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2
19 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2
20 Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer Completed NCT00664781 Phase 2
21 Toremifene in Treating Patients With Ovarian Cancer Completed NCT00003865 Phase 2
22 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
23 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
24 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
25 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2
26 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2
27 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
28 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting NCT02283658 Phase 2
29 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Not yet recruiting NCT02978625 Phase 2
30 Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma Terminated NCT00653328 Phase 2
31 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2
32 Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists Terminated NCT00447226 Phase 2
33 Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer Completed NCT01096394 Phase 1
34 Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors Completed NCT01198184 Phase 1
35 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
36 HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma Recruiting NCT02947152 Phase 1
37 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1
38 Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn NCT02050009 Phase 1
39 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
40 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497
41 Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions Recruiting NCT02494388 Early Phase 1
42 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837
43 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Not yet recruiting NCT02774395
44 Research Study in Patients With Advanced Ovarian Epithelial Cancer Withdrawn NCT00053235

Search NIH Clinical Center for Papillary Serous Adenocarcinoma

Genetic Tests for Papillary Serous Adenocarcinoma

Anatomical Context for Papillary Serous Adenocarcinoma

MalaCards organs/tissues related to Papillary Serous Adenocarcinoma:

39
Ovary, Cervix, Breast, Brain

Publications for Papillary Serous Adenocarcinoma

Articles related to Papillary Serous Adenocarcinoma:

(show all 32)
id Title Authors Year
1
Filarial worm residing in ovarian papillary serous adenocarcinoma-A rare case report. ( 27444355 )
2016
2
Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. ( 23290009 )
2013
3
Multiple brain metastases in a patient with uterine papillary serous adenocarcinoma: Treatment options for this rarely seen metastatic brain tumor. ( 24032086 )
2013
4
F-18 fluoride uptake in calcified extraosseous metastases from ovarian papillary serous adenocarcinoma. ( 22157054 )
2012
5
Malignant mixed mullerian tumor of endometrium coexisting with bilateral papillary serous adenocarcinoma of fallopian tube: a rare case report. ( 24293882 )
2012
6
Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer. ( 23155282 )
2012
7
Papillary serous adenocarcinoma of the uterine cervix: a case report. ( 21614930 )
2011
8
Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report. ( 19132421 )
2010
9
99mTc-MDP and 18F-FDG uptake in calcified metastatic lesions from ovarian papillary serous adenocarcinoma. ( 19936349 )
2009
10
Successful Treatment of Primary Vaginal Papillary Serous Adenocarcinoma Using Chemoradiation Followed by Brachytherapy. ( 20740170 )
2009
11
Malignant pericardial tamponade secondary to papillary serous adenocarcinoma of the ovary. ( 17491236 )
2007
12
A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. ( 16930493 )
2006
13
Pulmonary papillary serous adenocarcinoma with intraperitoneal and ovarian tumors: identification of primary site. A case report. ( 16515596 )
2006
14
Papillary serous adenocarcinoma of the endometrium: CT-pathologic correlation. ( 15150003 )
2004
15
Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma. ( 15285295 )
2004
16
Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma. ( 15228430 )
2004
17
Papillary serous adenocarcinoma of the ovary diagnosed after malignant pericardial tamponade and embolic stroke. ( 11855887 )
2002
18
Cerebellar metastasis from papillary serous adenocarcinoma of the ovary mimicking MAcniA"re's disease. A case report. ( 11304872 )
2001
19
Papillary serous adenocarcinoma of the endocervix: A rare neoplasm. Immunohistochemical profile. ( 11240696 )
2000
20
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? ( 11104623 )
2000
21
Supradiaphragmatic manifestations of papillary serous adenocarcinoma of the ovary. ( 10580766 )
1999
22
The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma. ( 10422674 )
1999
23
Multiple nodular metastases in mesenteric panniculitis by uterine papillary serous adenocarcinoma (UPSC): CT appearance of a case. ( 10416083 )
1999
24
Cytologic features of papillary serous adenocarcinoma of the uterine cervix. ( 9126137 )
1997
25
Histologic characterization of uterine papillary serous adenocarcinoma. ( 7705679 )
1995
26
Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. ( 7915964 )
1994
27
Papillary serous adenocarcinoma of the uterine cervix: a report of three cases. ( 1495949 )
1992
28
Papillary serous adenocarcinoma of the endometrium: a clinicopathologic study of 19 cases. ( 1634141 )
1992
29
Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. ( 2013445 )
1991
30
Invasive papillary serous adenocarcinoma of the endocervix in pregnancy; a case report. ( 1855609 )
1991
31
Papillary serous adenocarcinoma of the endometrium. ( 3960439 )
1986
32
Papillary serous adenocarcinoma. ( 18870241 )
1948

Variations for Papillary Serous Adenocarcinoma

Expression for Papillary Serous Adenocarcinoma

Search GEO for disease gene expression data for Papillary Serous Adenocarcinoma.

Pathways for Papillary Serous Adenocarcinoma

GO Terms for Papillary Serous Adenocarcinoma

Cellular components related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.63 BRCA2 NKX2-1 STK36
2 positive regulation of transcription, DNA-templated GO:0045893 9.56 BRCA1 BRCA2 NKX2-1 TP53
3 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.52 BRCA1 BRCA2
4 nucleotide-excision repair GO:0006289 9.51 BRCA2 TP53
5 DNA synthesis involved in DNA repair GO:0000731 9.49 BRCA1 BRCA2
6 response to gamma radiation GO:0010332 9.48 BRCA2 TP53
7 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.43 BRCA2 TP53
8 cell aging GO:0007569 9.4 BRCA2 TP53
9 strand displacement GO:0000732 9.37 BRCA1 BRCA2
10 positive regulation of cell cycle arrest GO:0071158 9.32 BRCA1 TP53
11 response to X-ray GO:0010165 9.16 BRCA2 TP53
12 chordate embryonic development GO:0043009 8.96 BRCA1 BRCA2
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Molecular functions related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.13 BRCA1 NKX2-1 TP53
2 enzyme binding GO:0019899 8.92 BRCA1 NKX2-1 PGR TP53

Sources for Papillary Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....